A coalition of leading tuberculosis (TB) experts and medical societies is calling for an urgent expansion of the European Medicines Agency (EMA) label for pretomanid, a key drug in the fight against multidrug-resistant TB (MDR-TB) and rifampicin-resistant TB (RR-TB). This appeal, in alignment with the latest World Health Organization (WHO) guidelines, aims to improve patient access to more effective and tolerable treatment regimens.
Pretomanid is currently approved by the EMA for use only in combination with bedaquiline and linezolid (BPaL regimen) and restricted to cases of extensively drug-resistant and select MDR-TB patients. However, global evidence from recent clinical trials — including NiX, ZeNix, and TB-PRACTECAL — demonstrates the effectiveness of an expanded regimen, BPaLM (including moxifloxacin), as the new standard of care for MDR/RR-TB. The WHO has recommended its programmatic use since 2022, urging national TB programs to adopt these regimens swiftly.
Despite these advancements, access to pretomanid remains limited in Europe. Expanding pretomanid’s label will ensure more patients benefit from shorter, safer, and more effective TB treatment.
This expert coalition proposes to EMA to act swiftly, updating pretomanid’s label to align with WHO recommendations and ensure equitable access to life-saving treatments across Europe.
“Updating the EMA label for pretomanid will be important to overcome problems of access to pretomanid that currently exist in Europe. The coalition of many professional societies in Respiratory Medicine and Infectious Diseases endorsing this open letter shows the importance of this problem”, says Prof. Christoph Lange from the Research Center Borstel, Leibniz Lung Center, scientist in the DZIF research area “Tuberculosis” and corresponding author of this initiative.
Access the publication in IJTLD OPEN, Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #15, 2 May 2025).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and EATG. Subscribe to the newsletter here.
Related HIV and Co-Infections News
-
[Press release] US and Global Fund expand commitment to long-acting HIV prevention as country rollout of lenacapavir accelerates
-
University of Manchester: Scientists develop a cheaper and more sustainable way to manufacture breakthrough HIV drug lenacapavir
-
AVAC: Abrupt shutdown of US global health supply chain raises risks for HIV, TB and malaria programs
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.